Combined use of antisense oligonucleotides for treating cancer, directed against the Polo-like kinase 1 and B cell leukemia/lymphoma 2 genes, having a synergistic effect

摘要

Combined use of an antisense oligodeoxynucleotide (ON1) against polo-like kinase 1 (Plk1) and an oligodeoxynucleotide (ON2) against the B cell leukemia/lymphoma 2 proto-oncogene (Bcl2) to prepare a composition for treating cancer.